

Remarks

The Examiner is thanked for the courtesies extended to Applicant's Representative in the telephonic interview on February 28, 2006, in which the Examiner suggested certain amendments to the claims.

Claims 53-55, 58-60, 63, 66-68, 70, 72-73, 78-79, and 81-82 are amended and claims 61-62 and 75 are canceled. The amendments are intended to advance the application and are not intended to concede to the Examiner's position or to prejudice the prosecution of the claims prior to amendment, which claims are present in a continuation of the above-identified application.

Claims 53-55, 58-60, 63-64, 66-68, 70, 72-74, 78-79, and 81-82 are now pending in this application.

Although claims 58-60, 63 and 66-68 were previously withdrawn from consideration, the Examiner is requested to rejoin those claims, as amended herein, with the pending claims. In particular, as claims 58-60 are method claims that depend on composition of matter claims 53-55, respectively, rejoinder of claims 58-60 with the elected claims is respectfully requested.

PRELIMINARY AMENDMENT

Serial Number: 09/047,652

Filing Date: March 25, 1998

Title: Peripheral-Type Benzodiazepine Receptor: A Tool for Detection, Diagnosis, Prognosis, and Treatment of Cancer

Page 6

Dkt: 1941.016US1

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612) 373-6959 to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.


Respectfully submitted,

VASSILIOS PAPADOPOULOS ET AL.,

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date April 14, 2006

By 
Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being filed using the USPTO's electronic filing system EFS-Web, and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 19 day of April, 2006.

Name

John D. Guspav-Watson

Signature

John D. Guspav-Watson